Overview

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-11-11

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficacy of JS212 combined with JS207, Toripalimab, JS213 combined or not combined with chemotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Treatments:

Injections
toripalimab